my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
12-07-2012: Oxford BioMedica plc announced that its partners at Cardiff University, Wales (UK) have initiated a Phase II trial to assess the safety and immunological activity of TroVax®, a therapeutic vaccine developed by Oxford BioMedica, in patients with inoperable metastatic colorectal cancer (CRC). The study will be funded by Cardiff University, with some funding awarded by Cancer Research Wales, and Oxford BioMedica will provide TroVax®. The trial is supported by the Experimental Cancer Medicine Centre (ECMC), Cardiff.
The randomised, open-label Phase II study, entitled “TaCTiCC” (TroVax® and Cyclophosphamide Treatment in Colorectal Cancer), builds on four previous Phase I/II trials conducted by Oxford BioMedica where TroVax® was given to patients with CRC, in addition to research into CRC undertaken by Dr Andrew Godkin and Dr Awen Gallimore at Cardiff University, Wales. Led by Dr Andrew Godkin, the study will enrol up to 54 patients with inoperable metastatic CRC. The study will evaluate whether TroVax®, administered alone or in combination with cyclophosphamide, is effective in the treatment of CRC. The study will assess anti-5T4 immune responses following treatment, in addition to secondary measures of clinical benefit including progression-free survival, objective response rate and overall survival.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Oxford BioMedica has appointed Martin Diggle as a non-executive director
Oxford BioMedica announced the appointment of Martin Diggle as a non-Executive Director of the Company, effective as of 4 October 2012.Martin is a founder of Vulpes Investment Management, a Cayman Fund Manager which currently manages five funds including the Vulpes Life Sciences Fund; Oxfor ... more
Oxford BioMedica plc announced that its partners at Cardiff University, Wales (UK) have initiated a Phase II trial to assess the safety and immunological activity of TroVax®, a therapeutic vaccine developed by Oxford BioMedica, in patients with inoperable metastatic colorectal cancer (CRC). ... more
Oxford BioMedica Announces Successful MHRA Inspection for its Proprietary Manufacturing Facility
Oxford BioMedica plc announces that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to manufacture bulk drug material for Investigational Medicinal Products (IMPs) at the Company’s specialist manufacturing facility in Cowley, Oxford. This re ... more
Oxford BioMedica is a biopharmaceutical company specializing in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. The Company has a platform of gene delivery technologies, whi ... more
Cardiff scientists bid to develop anthrax vaccine to counteract world bioterrorism threat
A team of Cardiff University scientists is leading new research to develop a vaccine against anthrax to help counteract the threat of bioterrorism. Working with scientists from the Republic of Georgia, Turkey and the USA, Professor Les Baillie from Cardiff University's School of Pharmacy an ... more
Oxford BioMedica plc announced that its partners at Cardiff University, Wales (UK) have initiated a Phase II trial to assess the safety and immunological activity of TroVax®, a therapeutic vaccine developed by Oxford BioMedica, in patients with inoperable metastatic colorectal cancer (CRC). ... more
Scientists shed new light on link between 'killer cells' and diabetes
Killer T-cells in the human body which help protect us from disease can inadvertently destroy cells that produce insulin, new research has uncovered. The study provides the first evidence of this mechanism in action and could offer new understanding of the cause of Type 1 diabetes.Professor ... more
Cardiff University is recognised in independent government assessments as one of Britain's leading teaching and research universities. Founded by Royal Charter in 1883, the University today combines impressive modern facilities and a dynamic approach to teaching and research with its proud ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
